Researchers found no significant differences in the risk of overall adverse events (AEs), but there were significant differences in grade 3 or higher AEs, serious AEs, treatment discontinuations due ...

Study authors said toripalimab plus chemotherapy could be a first-line treatment option, but authors of a related commentary said a global study may be needed to confirm that.

From 2000 to 2019, definitive treatment for those with intermediate- or high-risk disease and limited life expectancy increased.

Researchers sought to determine trends in participation and detection of CRC in multiround FIT-based CRC screening.

Cadonilimab plus chemotherapy, with or without bevacizumab, could be a safe and effective treatment option, according to researchers.